City

Paris (1)

Tucson (1)

Condition

Budesonide (2)

Acute Lung Injury (1)

Anosmia (1)

Chronic Lung Disease of Prematurity (1)

Infant, Extremely Premature (1)

Olfaction Disorders (1)

SARS-CoV-2 (1)

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 3 (1)

phase 4 (1)

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild (1)

University of Arizona (1)

Collaborator

Hopital Lariboisiere (1)

Intervention

budesonide nasal (1)

infants in the control group (s/p group) receive placebo (normal saline 1ml) (1)

infants in the study group (s/b group) will receive surfactant 2.5 mls/kg and budesonide 0.5 mg (1ml) (1)

physiological serum (1)

Study Documents

Intervention Type

drug (2)

other (1)

Funder Type

Other (2)

Study Type

Interventional (2)

budesonide

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity Trial in Tucson (Infants in the study group

Recruiting

Infant, Extremely Premature
+3 more

Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
Infants in the control group (S/P group) receive placebo (Normal saline 1mL)

Tucson, Arizona

University of Arizona

Oct 31, 2022

Budesonide, Olfaction Disorders, SARS-CoV-2 Trial in Paris (Budesonide Nasal, Physiological serum)

Completed

Budesonide
+3 more

Budesonide Nasal
Physiological serum

Paris, France

Amélie YAvchitz

Aug 2, 2021